Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer

@article{Sun2019AntiPD1TC,
  title={Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer},
  author={Danyang Sun and Junxun Ma and Jinliang Wang and Chun Xiao Han and Yuanyu Qian and Guangying Chen and Xiaoyan Li and Juan Zhang and Pengfei Cui and Wushuang Du and Zhaozhen Wu and Shixue Chen and Xuan Zheng and Zhichao Yue and Jia Song and Chan Gao and Xiaochen Zhao and Shangli Cai and Yi Hu},
  journal={Cancer Immunology, Immunotherapy},
  year={2019},
  volume={68},
  pages={1527 - 1535}
}
Evidence for the efficacy of immunotherapy in biliary tract cancer (BTC) is limited and unsatisfactory. Chinese BTC patients receiving a PD-1 inhibitor with chemotherapy, PD-1 inhibitor monotherapy or chemotherapy alone were retrospectively analyzed. The primary outcome was overall survival (OS). The key secondary outcomes were progression-free survival (PFS) and safety. Patients previously treated with any agent targeting T cell costimulation or immune checkpoints were excluded. The study… CONTINUE READING

Figures, Tables, and Topics from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 37 REFERENCES

Pembrolizumab for advanced biliary adenocarcinoma: results from the multicohort, phase 2 KEYNOTE-158 study

M Uene, HC Chung, +3 authors L Xu
  • Ann Oncol 29(Suppl
  • 2018
VIEW 1 EXCERPT